NovelStem International Corp.
NSTM - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$493.33K
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $493,325.00 |
|---|---|
| Enterprise Value | - |
| Earnings per Share | $0.05 |
| Beta | 2.47 |
| Outstanding Shares | 49,332,455 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -1.54 |
|---|---|
| PEG | 1.49 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About NovelStem International Corp.
2 employees
CEO: Jan H. Loeb
NovelStem International Corp. concentrates its efforts on pioneering and introducing diagnostic solutions for cancer treatment, specifically with the goal of mitigating chemotherapy resistance. The company, which commenced operations in ...